Delayed reduction in left ventricular function following treatment of non-Hodgkin's lymphoma with chemotherapy and rituximab, unrelated to acute infusion reaction

Cardiology

Volumn 105, Issue 3, 2006, Pages 184-187

  Kanamori, Hiroe ^a   Tsutsumi, Yutaka ^a   Mori, Akio ^a   Kawamura, Takahito ^a   Obara, Shinji ^a   Shimoyama, Norihiko ^a   Tanaka, Junji ^b   Asaka, Masahiro ^b   Imamura, Masahiro ^b   Masauzi, Nobuo ^a  

^a Hakodate Municipal Hospital   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiac function; Fibrosis; Non hodgkin's lymphoma; Rituximab; Transforming growth factor

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MONOCLONAL ANTIBODY; PREDNISOLONE; RETICULIN; RITUXIMAB; TRANSFORMING GROWTH FACTOR BETA; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CARDIAC PATIENT; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; FIBROSIS; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE CELL; HIGH RISK PATIENT; HUMAN; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG HYPERSENSITIVITY; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYOCARDIUM; RETICULIN; TRANSFORMING GROWTH FACTOR BETA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33645472361     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091416     Document Type: Article

References (14)

1. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR: Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-445.
2. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-2466.
3. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R: Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999;17:1851-1857.
4. Coiffier B: Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol 2002;29:30-35.
5. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-2193.
6. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
7. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing of refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-1932.
8. Foran JM, Rohatiner AZS, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PWM, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317-324.
9. Coiffer B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, van den Neste E, Salles G, Gaulard P, Reyes F, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
10. Ogura M, Kagami Y, Taji H, Suzuki R, Miura K, Takeuchi T, Morishima Y: Pilot phase I/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma. Int J Haematol 2003;77:503-511.
11. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217-2224.
12. Mavroidis M, Capetanaki Y: Extensive induction of important mediators of fibrosis and dystrophic calcification in desmin-deficient cardiomyopathy. Am J Pathol 2002;160:943-952.
13. Way KJ, Isshiki K, Suzuma K, Yokota T, Zagelsky D, Schoen FJ, Sandusky GE, Pechous PA, Vlahos CJ, Wakasaki H, King GL: Expression of connective tissue growth factors is increased in injured myocardium associated with protein kinase Cβ2 activation and diabetes. Diabetes 2002;51:2709-2718.
14. Ma M, Watanabe K, Wahed MI, Inoue M, Sekiguchi T, Kouda T, Ohta Y, Nakazawa M, Yoshida Y, Yamamoto T, Hanawa H, Kodama M, Fuse K, Aizawa Y: Inhibition of progression of heart failure and expression of TGF-beta 1 mRNA in rats with heart failure by the ACE inhibitor quinapril. J Cardiavasc Pharmacol 2001;38(suppl 1):S51-S54.